Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:03:44 EDT Sun 05 May 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:SGMO from 2023-05-04 to 2024-05-03 - 19 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-05-02 16:15
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
2024-04-22 16:35
U
U:SGMO
News Release
200
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2024-03-22 08:05
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
2024-03-13 08:05
U
U:SGMO
News Release
200
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2024-03-13 08:01
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
2024-03-12 18:30
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
2024-02-12 08:05
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
2024-02-05 18:01
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
2023-11-01 16:01
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
2023-10-25 16:15
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
2023-10-24 02:01
U
U:SGMO
News Release
200
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2023-09-20 16:15
U
U:SGMO
News Release
200
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
2023-08-08 16:01
U
U:SGMO
News Release
200
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
2023-08-01 16:15
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
2023-07-20 08:05
U
U:SGMO
News Release
200
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
2023-07-17 08:05
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
2023-06-29 08:05
U
U:SGMO
News Release
200
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
2023-05-22 08:05
U
U:SGMO
News Release
200
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
2023-05-16 08:00
U
U:SGMO
News Release
200
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer